Szekely E - Search Results

1

Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer.

Olah C, Reis H, Hoffmann MJ, Mairinger F, Ting S, Hadaschik B, Krafft U, Grünwald V, Nyirady P, Varadi M, Győrffy B, Kiss A, Szekely E, Sjödahl G, Szarvas T. Olah C, et al. Among authors: szekely e. Cancer Med. 2023 Mar;12(5):5222-5232. doi: 10.1002/cam4.5324. Epub 2022 Oct 7. Cancer Med. 2023. PMID: 36204983 Free PMC article.

2

STIP1 Tissue Expression Is Associated with Survival in Chemotherapy-Treated Bladder Cancer Patients.

Krafft U, Tschirdewahn S, Hess J, Harke NN, Hadaschik BA, Nyirády P, Szendröi A, Szücs M, Módos O, Olah C, Székely E, Reis H, Szarvas T. Krafft U, et al. Among authors: szekely e. Pathol Oncol Res. 2020 Apr;26(2):1243-1249. doi: 10.1007/s12253-019-00689-y. Epub 2019 Jun 27. Pathol Oncol Res. 2020. PMID: 31250373 Free article.

3

Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer.

Krafft U, Tschirdewahn S, Hess J, Harke NN, Hadaschik B, Olah C, Krege S, Nyirády P, Szendröi A, Szücs M, Módos O, Székely E, Reis H, Szarvas T. Krafft U, et al. Among authors: szekely e. Urol Oncol. 2019 Nov;37(11):810.e7-810.e15. doi: 10.1016/j.urolonc.2019.04.015. Epub 2019 Apr 30. Urol Oncol. 2019. PMID: 31053526

4

MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients.

Szarvas T, Hoffmann MJ, Olah C, Szekely E, Kiss A, Hess J, Tschirdewahn S, Hadaschik B, Grotheer V, Nyirady P, Csizmarik A, Varadi M, Reis H. Szarvas T, et al. Among authors: szekely e. Diagnostics (Basel). 2020 Dec 31;11(1):48. doi: 10.3390/diagnostics11010048. Diagnostics (Basel). 2020. PMID: 33396213 Free PMC article.

5

Expression of claudins and their prognostic significance in noninvasive urothelial neoplasms of the human urinary bladder.

Székely E, Törzsök P, Riesz P, Korompay A, Fintha A, Székely T, Lotz G, Nyirády P, Romics I, Tímár J, Schaff Z, Kiss A. Székely E, et al. Among authors: szekely t. J Histochem Cytochem. 2011 Oct;59(10):932-41. doi: 10.1369/0022155411418829. Epub 2011 Aug 10. J Histochem Cytochem. 2011. PMID: 21832144 Free PMC article.

6

Claudins and ki-67: potential markers to differentiate low- and high-grade transitional cell carcinomas of the urinary bladder.

Törzsök P, Riesz P, Kenessey I, Székely E, Somorácz A, Nyirády P, Romics I, Schaff Z, Lotz G, Kiss A. Törzsök P, et al. Among authors: szekely e. J Histochem Cytochem. 2011 Nov;59(11):1022-30. doi: 10.1369/0022155411424606. J Histochem Cytochem. 2011. PMID: 22043024 Free PMC article.

7

Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer.

Kocsmár I, Kocsmár É, Pajor G, Kulka J, Székely E, Kristiansen G, Schilling O, Nyirády P, Kiss A, Schaff Z, Riesz P, Lotz G. Kocsmár I, et al. Among authors: szekely e. Cancers (Basel). 2022 Sep 21;14(19):4570. doi: 10.3390/cancers14194570. Cancers (Basel). 2022. PMID: 36230493 Free PMC article.

8

Development and Initial Testing of a Modified UroVysion-Based Fluorescence In Situ Hybridization Score for Prediction of Progression in Bladder Cancer.

Kocsmár I, Pajor G, Gyöngyösi B, Székely E, Varga M, Kocsmár É, Kenessey I, Beöthe T, Süle N, Majoros A, Szendrői A, Nyírády P, Kiss A, Riesz P, Lotz G. Kocsmár I, et al. Among authors: szekely e. Am J Clin Pathol. 2020 Jan 2;153(2):274-284. doi: 10.1093/ajcp/aqz165. Am J Clin Pathol. 2020. PMID: 31732739

9

Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma.

Gyöngyösi B, Végh É, Járay B, Székely E, Fassan M, Bodoky G, Schaff Z, Kiss A. Gyöngyösi B, et al. Among authors: szekely e. J Histochem Cytochem. 2014 Aug;62(8):547-55. doi: 10.1369/0022155414537277. Epub 2014 May 7. J Histochem Cytochem. 2014. PMID: 24804874

10

The influence of expertise of the surgical pathologist to undergrading, upgrading, and understaging of prostate cancer in patients undergoing subsequent radical prostatectomy.

Majoros A, Szász AM, Nyirády P, Székely E, Riesz P, Szendrői A, Keszthelyi A, Kulka J, Romics I. Majoros A, et al. Among authors: szekely e. Int Urol Nephrol. 2014 Feb;46(2):371-7. doi: 10.1007/s11255-013-0538-4. Epub 2013 Aug 30. Int Urol Nephrol. 2014. PMID: 23990495

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

298 results

Search Page